Physician profile
Eric Schreader
NPI 1235816653
$6,095.01
in general payments reported to CMS, 2019-2025
29 companies · $3,032 in 2025
The $3,032 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,824 · 2024: $1,238 · 2025: $3,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270 · Travel and Lodging: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.99 |
| Travel and Lodging | $825.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $616.16 | 2023 | |
| Tg Therapeutics, INC. | $512.26 | 2023-2025 | |
| Amgen INC. | $499.96 | 2025 | Otezla, Repatha, Krystexxa |
| Prodigy Surgical Distribution, INC. | $498.17 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $432.86 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $278.29 | 2025 | Symbravo, Auvelity |
| Genzyme Corporation | $257.75 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $220.59 | 2024-2025 | Austedo Xr |
| Abbvie INC. | $219.83 | 2023 | |
| Smith+Nephew, INC. | $195.38 | 2025 | Bone Anchors With Arthroscopic Delivery System |
| Boston Scientific Corporation | $152.06 | 2025 | Watchman Flx |
| Madrigal Pharmaceuticals | $147.24 | 2025 | Rezdiffra |
| Pharmacosmos Therapeutics INC. | $145.40 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $135.48 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $134.98 | 2025 | Givlaari |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $132.83 | 2024 | Aptima |
| Inspire Medical Systems, INC. | $126.80 | 2023 | Inspire |
| Genentech USA, INC. | $126.04 | 2025 | Xolair |
| Grifols USA, LLC | $124.99 | 2025 | Prolastin-C Liquid |
| Csl Behring | $124.99 | 2024 | Hizentra |
| Novo Nordisk INC | $124.99 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $124.99 | 2024 | |
| Exact Sciences Corporation | $119.04 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Intercept Pharmaceuticals, INC. | $113.54 | 2023 | Ocaliva |
| Gilead Sciences, INC. | $112.79 | 2024 | Epclusa |
| Sanofi-Aventis U.S. LLC | $102.60 | 2025 | |
| Luye Pharma (USA) Ltd. | $100.00 | 2025 | Erzofri Extended-Release |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schreader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.